^
    Back
    Association details:
    Biomarker:EZH2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:azacitidine (DNMT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cancers (Basel)
    Title:

    The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

    Published date:
    05/18/2021
    Excerpt:
    ...newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status...Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis.
    DOI:
    10.3390/cancers13102458
    Trial ID:
    FLUGAZA